Research graph
References from An Investigator-Initiated Randomized Controlled Trial of Human Recombinant Platelet-Derived Growth Factor in Addition to Urea Cream for Prevention of Multikinase Inhibitor-Associated Hand-Foot Skin Reaction (HFSR)-PaRTH Trial. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1634/theoncologist.2011-0115
10.1634/theoncologist.2011-0115 · 2011 · External reference
Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial
10.1001/jamaoncol.2017.1269 · 2017 · External reference
Dermatological toxicity associated with targeted therapies in cancer: optimal management
10.1007/s40257-014-0088-2 · 2014 · External reference
Cutaneous side-effects of kinase inhibitors and blocking antibodies
10.1016/s1470-2045(05)70243-6 · 2005 · External reference
Unresolved reference
2014 · External reference
Unresolved reference
External reference
Cutaneous side effect of molecularly targeted therapies for the treatment of solid tumors
2018 · External reference
Van Cut sem E. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management
10.1093/annonc/mdv244 · 2015 · External reference
Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors
10.1016/s1548-5315(11)70385-0 · 2010 · External reference
Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study
2022 · External reference
Chemotherapy-induced hand-foot syndrome: clinical and epidemiological approach to cancer patients
10.32635/2176-9745.rbc.2019v65n2.285 · 2019 · External reference
Unresolved reference
2019 · External reference
Multicenter, double-blind, placebo-controlled trial of becaplermin gel for the treatment of diabetic neuropathic ulcers
1998 · External reference
Therapeutic role of growth factors in treating diabetic wound
10.4239/wjd.v14.i4.364 · 2023 · External reference
Topical Biological Agents as Adjuncts to Improve Wound Healing in Chronic Diabetic Wounds: A Systematic Review of Clinical Evidence and Future Directions
External reference
Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical pre sentation, etiology, pathogenesis, and management
10.1016/j.jaad.2014.03.019 · 2014 · External reference
10.1016/j.jss.2007.02.044
10.1016/j.jss.2007.02.044 · External reference
Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial
10.1001/jamaoncol.2017.1269 · ExternalCitation · doi-reference
Dermatological toxicity associated with targeted therapies in cancer: optimal management
10.1007/s40257-014-0088-2 · ExternalCitation · doi-reference
Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical pre sentation, etiology, pathogenesis, and management
10.1016/j.jaad.2014.03.019 · ExternalCitation · doi-reference
10.1016/j.jss.2007.02.044
10.1016/j.jss.2007.02.044 · ExternalCitation · doi-reference
Cutaneous side-effects of kinase inhibitors and blocking antibodies
10.1016/s1470-2045(05)70243-6 · ExternalCitation · doi-reference
Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors
10.1016/s1548-5315(11)70385-0 · ExternalCitation · doi-reference
Van Cut sem E. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management
10.1093/annonc/mdv244 · ExternalCitation · doi-reference
10.1634/theoncologist.2011-0115
10.1634/theoncologist.2011-0115 · ExternalCitation · doi-reference
Chemotherapy-induced hand-foot syndrome: clinical and epidemiological approach to cancer patients
10.32635/2176-9745.rbc.2019v65n2.285 · ExternalCitation · doi-reference
Therapeutic role of growth factors in treating diabetic wound
10.4239/wjd.v14.i4.364 · ExternalCitation · doi-reference
